Eisai Co., Ltd. and Biogen Idec have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401. Eisai also has an option to jointly develop and commercialize two of Biogen’s AD candidates, an anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.   The collaboration will initially involve the co-development and commercialization of Eisai’s two candidates: E2609, a β-site amyloid precursor pro...